Brief: Medincell's Partner Teva Today Announced Refiling For Approval Of Mdc-Irm And Confirmed Planned Launch In U.S. In H1 2023

Medincell SA

03/11/2022 19:18

Medincell SA  MEDCL.PA :
    * MEDINCELL'S PARTNER TEVA TODAY ANNOUNCED REFILING FOR
APPROVAL
OF MDC-IRM AND CONFIRMED PLANNED LAUNCH IN U.S. IN H1 2023
    * MEDINCELL SA - TEVA NOW EXPECTS REVIEW AND APPROVAL TO
TAKE UP
TO SIX MONTHS POST RESUBMISSION
    * MEDINCELL SA - TEVA IS CONFIDENT THAT IT WILL ACHIEVE FDA
APPROVAL AND LAUNCH MDC-IRM UNDER BRAND NAME UZEDY™ IN FIRST
HALF OF 2023

Source text for Eikon:  ID:nBwb29fTMa 
Further company coverage:  MEDCL.PA